Novartis says Alcon's Travatan receives EU approval

ZURICH (Reuters) - Swiss pharmaceutical group Novartis said on Tuesday the European Commission had approved an additional treatment for its eyecare unit Alcon's Travatan treatment for glaucoma, a chronic, sight-threatening eye disease.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Conclusions: LSCD associated with glaucoma surgery has clinical features distinct from LSCD resulting from other etiologies. Further study is required to delineate the full impact of glaucoma surgery on limbal stem cell function and survival.
Source: Cornea - Category: Opthalmology Tags: Clinical Science Source Type: research
Conclusions: Our 5-year clinical results of nDSAEK and DSAEK did not show significant differences at almost all points.
Source: Cornea - Category: Opthalmology Tags: Clinical Science Source Type: research
Publication date: Available online 30 March 2020Source: Microvascular ResearchAuthor(s): Aizhu Tao, Yuanbo Liang, Juanjuan Chen, Haishuang Hu, Qiangjie Huang, Jingwei Zheng, Cong Ye, Fan Lu
Source: Microvascular Research - Category: Biochemistry Source Type: research
Journal of Ocular Pharmacology and Therapeutics, Ahead of Print.
Source: Journal of Ocular Pharmacology and Therapeutics - Category: Opthalmology Authors: Source Type: research
AbstractPurpose of ReviewTo review the current understanding of the pathophysiology and management of aqueous misdirection syndrome.Recent FindingsAqueous misdirection syndrome represents a spectrum of disorders that converge on a common pathway of increasing posterior segment pressure and secondary angle closure glaucoma. Although the etiology of aqueous misdirection remains unclear and is likely multifactorial, recent data supports choroidal expansion as an inciting event in the pathogenesis of the syndrome. As such, the term aqueous misdirection may be a misnomer. Some would argue that the use of terminology such as acu...
Source: Current Ophthalmology Reports - Category: Opthalmology Source Type: research
Second Sight Medical Products is the latest medtech company to face tough losses as a result of the financial impact of the novel coronavirus (SARS-CoV-2). The Sylmar, CA-based company is laying off 84 of its 108 employees and said it intends to wind-down operations. The firm develops implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals. FDA greenlit the Argus II retinal prosthesis system in 2013. Plans now call for the Second Sight to retain an adviser experienced in winding down operations to guide the board on the next steps. Any wind down activity, if impl...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Business Source Type: news
Conditions:   Glaucoma;   Diabetic Retinopathy;   Refractive Errors;   Cataract;   Behavior, Health Interventions:   Other: No Financial Incentive;   Behavioral: Financial Incentive Sponsors:   University of Alabama at Birmingham;   Centers for Disease Control and Prevention Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 28 March 2020Source: Autoimmunity ReviewsAuthor(s): Orna Geyer, Yoram Levo
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research
AbstractPurposeTo evaluate the safety and the adjunctive effect of intracameral tissue plasminogen activator (tPA) in trabeculectomy for patients with primary open-angle glaucoma (POAG).MethodsThis was a prospective, randomized study consisting of patients with POAG who underwent trabeculectomy in Tel Aviv Medical Center between March 2013 and December 2014. Patients were randomly assigned to two groups: Group 1 underwent mitomycin C (MMC) trabeculectomy and group 2 underwent MMC trabeculectomy with intracameral tPA. Complete and overall success were defined as intraocular pressure (IOP) between 5 and 18  mmHg and at ...
Source: International Ophthalmology - Category: Opthalmology Source Type: research
This study was designed to measure retinal perfusion density changes on optical coherence tomography (OCT) angiography and OCT thickness alterations associated with acutely increased IOP after intravitreal injections. Methods: Retrospective observational clinical study of 40 eyes (39 patients) with various retinopathies from October 2016 to June 2017 at a tertiary care retina clinic in NYC. Patients were older than 18 years, with vision>20/100, able to fixate and without media opacities precluding OCT angiography, receiving intravitreal bevacizumab or aflibercept for diabetic retinopathy, retinal vein occlusion, macu...
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research
More News: Eyes | Glaucoma | Health | Travatan